Benefits for MI, CV death, hospitalization for HF, all-cause mortality, and the composite of CV death and hospitalization for HF were also observed with SGLT2 inhibitors, although high between-study heterogeneity was observed for outcomes of CV death and all-cause mortality [75]. The gene discussed is SLC5A2; the disease is hydrops fetalis.